The results showed no statistical difference in outcome for patients treated with gefitinib, even though there was a small trend toward improved PFS, OS and RR in favor of gefitinib.
← all excerpts
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
2
—
—
The sentences
The subgroup analysis did not show any statistical difference in survival except for a slight trend toward improved survival for patients with adenocarcinoma; these patients received chemotherapy for more than 90 days in the gefitinib 250 mg/day arm, suggesting a possible effect of gefitinib monotherapy as maintenance therapy.